Absolute quantification of graft-derived cell-free DNA as a marker of rejection and graft injury in kidney transplantation – results from a prospective observational trial (Oellerich et al. AACC 2018)
Chronix Biomedical reports a positive interim analysis of its ongoing validation study of its Copy Number Instability (CNI)-based therapeutic monitoring test in pancreatic cancer. The study compares the accuracy of Chronix’s CNI-based test at predicting a clinical response, as early as after the first cycle of chemotherapy compared to CA19-9, a commonly used biomarker.
This is the third year that Chronix is presenting its study results at ASCO — this year’s results are from a blinded prospective study validating the use of a CNI Monitor blood test to predict the treatment outcome of patients undergoing immunotherapy.
Experts on Chronix Biomedical CNI Monitor test. Testing for drug efficacy. #TheTurningPointInCancerFight